transferrin-ABR immunotoxin
This immunotoxin was achieved by conjugating/fusing the transferrin to Abrin. It was expressed in CHO and purified with affinity chromatography. The immunotoxin selectively binds to tumor cells. Once bind, the abrin is subsequently engulfed and enters the inner parts of the cell where it reacts with a ribosomal subunit. It interferes with the normal protein synthesis process of the cell and then inhibits cell protein synthesis. It was designed for treatment of myelogenous leukemia.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AGTO-G074A |
| Pricing | Inquiry |
| Applications | This product is suitable for use in cytotoxicity assay, functional assay and immunotherapy. |
| Host | Human |
| Target | BDP1 |
| Species Reactivity | Human |